Published online before print August 25, 2008, doi: 10.1161/CIRCULATIONAHA.107.752147
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:1146-1154.)
© 2008 American Heart Association, Inc.
Interventional Cardiology |
Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease
A Meta-Analysis With 5-Year Patient-Level Data From the ARTS, ERACI-II, MASS-II, and SoS Trials
From Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands (J.D., E.B., P.W.S.); Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, UK (M.F., J.B., R.S.); Otamendi Hospital, Buenos Aires, Argentina (A.R., G.R.-G.); and Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil (W.A.H., P.A.L.).
Correspondence to Professor P.W. Serruys, MD, PhD, Thoraxcenter, Ba-583, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands. E-mail p.w.j.c.serruys{at}erasmusmc.nl
Received November 13, 2007; accepted June 30, 2008.
Background— Randomized trials that studied clinical outcomes after percutaneous coronary intervention (PCI) with bare metal stenting versus coronary artery bypass grafting (CABG) are underpowered to properly assess safety end points like death, stroke, and myocardial infarction. Pooling data from randomized controlled trials increases the statistical power and allows better assessment of the treatment effect in high-risk subgroups.
Methods and Results— We performed a pooled analysis of 3051 patients in 4 randomized trials evaluating the relative safety and efficacy of PCI with stenting and CABG at 5 years for the treatment of multivessel coronary artery disease. The primary end point was the composite end point of death, stroke, or myocardial infarction. The secondary end point was the occurrence of major adverse cardiac and cerebrovascular accidents, death, stroke, myocardial infarction, and repeat revascularization. We tested for heterogeneities in treatment effect in patient subgroups. At 5 years, the cumulative incidence of death, myocardial infarction, and stroke was similar in patients randomized to PCI with stenting versus CABG (16.7% versus 16.9%, respectively; hazard ratio, 1.04, 95% confidence interval, 0.86 to 1.27; P=0.69). Repeat revascularization, however, occurred significantly more frequently after PCI than CABG (29.0% versus 7.9%, respectively; hazard ratio, 0.23; 95% confidence interval, 0.18 to 0.29; P<0.001). Major adverse cardiac and cerebrovascular events were significantly higher in the PCI than the CABG group (39.2% versus 23.0%, respectively; hazard ratio, 0.53; 95% confidence interval, 0.45 to 0.61; P<0.001). No heterogeneity of treatment effect was found in the subgroups, including diabetic patients and those presenting with 3-vessel disease.
Conclusions— In this pooled analysis of 4 randomized trials, PCI with stenting was associated with a long-term safety profile similar to that of CABG. However, as a result of persistently lower repeat revascularization rates in the CABG patients, overall major adverse cardiac and cerebrovascular event rates were significantly lower in the CABG group at 5 years.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 118: 1113-1114.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  T. A. Schwann, A. Zacharias, C. J. Riordan, S. J. Durham, A. S. Shah, and R. H. Habib Sequential radial artery grafts for multivessel coronary artery bypass graft surgery: 10-year survival and angiography results. Ann. Thorac. Surg., July 1, 2009; 88(1): 31 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Kukreja, P W Serruys, B De Bruyne, A Colombo, C Macaya, G Richardt, J Fajadet, C Hamm, D Goedhart, N Macours, et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II) Heart, July 1, 2009; 95(13): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Soran, A. Manchanda, and S. Schueler Percutaneous coronary intervention versus coronary artery bypass surgery in multivessel disease: a current perspective Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 666 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A A Fox COURAGE to change practice? Revascularisation in patients with stable coronary artery disease Heart, May 1, 2009; 95(9): 689 - 692. [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Serruys, M.-C. Morice, A. P. Kappetein, A. Colombo, D. R. Holmes, M. J. Mack, E. Stahle, T. E. Feldman, M. van den Brand, E. J. Bass, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease N. Engl. J. Med., March 5, 2009; 360(10): 961 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Lange and L. D. Hillis Coronary Revascularization in Context N. Engl. J. Med., March 5, 2009; 360(10): 1024 - 1026. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Smith Surgery, Not Percutaneous Revascularization, Is the Preferred Strategy for Patients With Significant Left Main Coronary Stenosis Circulation, February 24, 2009; 119(7): 1013 - 1020. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Rodriguez and R. Waksman Sirolimus-Eluting Stents or Vascular Brachytherapy for In-Stent Restenosis After 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stent Versus Vascular Brachytherapy for In-Stent Restenosis) Trial: A Call for Caution? J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 75 - 76. [Full Text] [PDF]
|
|